Next-gen gene editing upstart is grabbing the brass ring with a $150M crossover play to back its bid on a cure for sickle cell disease
Back in the spring of 2014, Versant put together a tidy $25 million launch round for a small upstart with big dreams called CRISPR Therapeutics. They had an impressive brain trust, headed by CRISPR/Cas9 innovator — and now Nobel winner — Emmanuelle Charpentier. And that exclusive band of gene editing pioneers included Matt Porteus out of Stanford.
CRISPR Therapeutics, of course, went on to become a leader in the gene editing field, now partnered with Vertex on a cutting-edge program for sickle cell disease. The biotech has a market cap brushing up against $10 billion — serious money in an era that’s turned its attention to biotech and the future of medicine.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.